Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $188.8 million.

  • Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) rose 20.93% to $228.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.4 million, marking a year-over-year increase of 20.93%. This contributed to the annual value of $188.8 million for FY2024, which is 7.92% up from last year.
  • As of FY2024, Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) stood at $188.8 million, which was up 7.92% from $175.0 million recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) peaked at $188.8 million during FY2024, and registered a low of $150.0 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $175.0 million (2023), whereas its average is $177.9 million.
  • Data for Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY grew of 12.38% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) stood at $150.0 million in 2020, then grew by 12.38% to $168.6 million in 2021, then grew by 0.84% to $170.0 million in 2022, then climbed by 2.95% to $175.0 million in 2023, then increased by 7.92% to $188.8 million in 2024.